Biocon (a Biotechnology Company with headquarters in Bangalore, India) has received the marketing authorization from the Drugs Controller general of India for Novel Biologic Itolizumab (used for the treatment of chronic plaque Psoriasis). Itolizumab has an excellent safety profile as indicated during the 52-week clinical study conducted in India.
This approval paves the way for the launch, later in 2013, of Biocon’s Alzumab (a differentiated biologic drug) in India. It will treat moderate-to-severe Psoriasis and will be manufactured at the company’s facility in Bangalore.
According to Kiran Mazumdar-Shaw, Managing Director of Biocon, this is the company’s second novel biologic that they have developed in India after BioMab EGFR which is an anti-cancer monoclonal antibody.
Last updated: December 26th, 2025
